XML 70 R53.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Royalty and Commercial Payment Purchase Agreements - Agenus (Details) $ in Thousands |  | 1 Months Ended | 6 Months Ended |
--- | --- | --- | --- | ---
Sep. 20, 2018 USD ($) product | Nov. 30, 2020 USD ($) | Jun. 30, 2024 USD ($) | Jun. 30, 2023 USD ($) | Dec. 31, 2023 USD ($)
Agreements |  |  |  |  |
Payments of consideration under RPAs, AAAs and CPPAs |  |  | $ 37,000 | $ 14,650 |
Short-term royalty and commercial payment receivables |  |  | 14,257 |  | $ 14,215
Royalty Purchase Agreement | Merck Immuno-Oncology Product | Agenus |  |  |  |  |
Agreements |  |  |  |  |
Amount of milestone payments earned under agreement |  | $ 10,000 |  |  |
Agenus | Royalty Purchase Agreement |  |  |  |  |
Agreements |  |  |  |  |
Payments of consideration under RPAs, AAAs and CPPAs | $ 15,000 |  |  |  |
Acquisition of royalty and commercial payment receivables, Long-Term | $ 15,000 |  |  |  |
Amount of allowance for credit losses |  |  | $ 0 |  | $ 0
Agenus | Royalty Purchase Agreement | Incyte Immuno-Oncology Assets |  |  |  |  |
Agreements |  |  |  |  |
Royalties entity has right to receive (as a percent) | 33.00% |  |  |  |
Number of licensed products related to milestone and royalties | product | 6 |  |  |  |
Milestone payments entity has right to receive (as a percent) | 10.00% |  |  |  |
Agenus | Royalty Purchase Agreement | Merck Immuno-Oncology Product |  |  |  |  |
Agreements |  |  |  |  |
Royalties entity has right to receive (as a percent) | 33.00% |  |  |  |
Milestone payments entity has right to receive (as a percent) | 10.00% |  |  |  |
Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones | $ 59,500 |  |  |  |
Amount of milestone payments earned under agreement |  | 1,000 |  |  |
Reduction in long-term royalty receivable balance due to receipt of payment |  | $ 1,000 |  |  |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details
Name: | us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of milestone achieved. + References No definition available. + Details
Name: | xoma_MilestoneAchieved
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of licensed products related to milestones and royalties purchased. + References No definition available. + Details
Name: | xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. + References No definition available. + Details
Name: | xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones. May also include clinical milestones. + References No definition available. + Details
Name: | xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of milestones entity has the right to receive as a percentage. + References No definition available. + Details
Name: | xoma_PurchasedPercentageOfMilestones
Namespace Prefix: | xoma_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Decrease in long-term rights receivable due to receipt of royalty and commercial payments. + References No definition available. + Details
Name: | xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer. + References No definition available. + Details
Name: | xoma_RightsReceivableCurrent
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Increase in long term rights receivable due acquisition of royalty, interest and commercial payment rights. + References No definition available. + Details
Name: | xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalties entity has the right to receive as a percentage of net sales. + References No definition available. + Details
Name: | xoma_RoyaltyReceivablePercentageOnNetSales
Namespace Prefix: | xoma_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_MerckImmunoOncologyProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=xoma_AgenusIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_AgenusIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_IncyteImmunoOncologyAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |